Prescribing trends for dabigatran etexilate in primary care.

Hdl Handle:
http://hdl.handle.net/10147/234492
Title:
Prescribing trends for dabigatran etexilate in primary care.
Authors:
McCullagh, L; Barry, M
Affiliation:
The National Centre for Pharmacoeconomics, St James's Hospital, Dublin 8. Imccullagh@stjames.ie
Citation:
Prescribing trends for dabigatran etexilate in primary care. 2012, 105 (5):134-6 Ir Med J
Publisher:
Irish Medical Journal (IMJ)
Journal:
Irish medical journal
Issue Date:
May-2012
URI:
http://hdl.handle.net/10147/234492
PubMed ID:
22803489
Abstract:
At the time of the analysis, dabigatran etexilate was licensed, in Ireland, for thromboprophylaxis in adults after elective total hip- and total knee-replacement only. A retrospective review (January 2010 to June 2011) of the National General Medical Services Prescription Database showed that 1929 patients had received prescriptions for dabigatran etexilate. Of these, 42% had received it for longer than the licensed maximum duration (at that time) of 35 days. The Eastern Health board dabigatran etexilate cohort (n = 510) was analysed further. Here 64.5% had received the drug for longer than 35 days. Seventy-six (32.5%) of the 234 patients who had received more than 90 days of dabigatran etexilate had concurrently received rate/rhythm control therapy. Likewise, 47 (31%) of the 152 patients who had received more than 180 days of dabigatran etexilate had been co-prescribed rate/rhythm control therapy. It is possible that dabigatran etexilate had been prescribed for stroke prevention in atrial fibrillation.
Item Type:
Report
Language:
en
ISSN:
0332-3102

Full metadata record

DC FieldValue Language
dc.contributor.authorMcCullagh, Len_GB
dc.contributor.authorBarry, Men_GB
dc.date.accessioned2012-07-19T09:51:13Z-
dc.date.available2012-07-19T09:51:13Z-
dc.date.issued2012-05-
dc.identifier.citationPrescribing trends for dabigatran etexilate in primary care. 2012, 105 (5):134-6 Ir Med Jen_GB
dc.identifier.issn0332-3102-
dc.identifier.pmid22803489-
dc.identifier.urihttp://hdl.handle.net/10147/234492-
dc.description.abstractAt the time of the analysis, dabigatran etexilate was licensed, in Ireland, for thromboprophylaxis in adults after elective total hip- and total knee-replacement only. A retrospective review (January 2010 to June 2011) of the National General Medical Services Prescription Database showed that 1929 patients had received prescriptions for dabigatran etexilate. Of these, 42% had received it for longer than the licensed maximum duration (at that time) of 35 days. The Eastern Health board dabigatran etexilate cohort (n = 510) was analysed further. Here 64.5% had received the drug for longer than 35 days. Seventy-six (32.5%) of the 234 patients who had received more than 90 days of dabigatran etexilate had concurrently received rate/rhythm control therapy. Likewise, 47 (31%) of the 152 patients who had received more than 180 days of dabigatran etexilate had been co-prescribed rate/rhythm control therapy. It is possible that dabigatran etexilate had been prescribed for stroke prevention in atrial fibrillation.en_GB
dc.language.isoenen
dc.publisherIrish Medical Journal (IMJ)en_GB
dc.rightsArchived with thanks to Irish medical journalen_GB
dc.titlePrescribing trends for dabigatran etexilate in primary care.en_GB
dc.typeReporten
dc.contributor.departmentThe National Centre for Pharmacoeconomics, St James's Hospital, Dublin 8. Imccullagh@stjames.ieen_GB
dc.identifier.journalIrish medical journalen_GB
dc.description.provinceLeinsteren
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.